Oligonucleotide News and Research

RSS

Single-patient pilot study shows the ability of antisense oligonucleotide to suppress mutant ALS gene

Using a short, synthetic chain of chemically modified nucleotides engineered in the RNA Therapeutics Institute at UMass Chan Medical School, Robert H. Brown Jr., DPhil, MD, Jonathan Watts, PhD, and colleagues have shown the ability to suppress mutant forms of an ALS gene known as C9ORF72 in a single-patient pilot study.

24 Dec 2021

Exploring the impact of DNA nanoswitches in RNA purification

A new study reports a tool to enable RNA purification by sequence, helping to determine the structure, chemical modifications, and interactions between different RNA molecules.

15 Dec 2021

An assessment of pH-sensitive cationic lipid nanoparticles for drug delivery

A recent review looks at the molecular design of pH-sensitive cationic lipids and their applications for various tissues and cell types.

7 Dec 2021

Colorimetric detection of SARS-CoV-2 viral RNA by an in vitro transcription/translation assay

This work has emphasized the clinical and translational potential of paper-based biosensors.

6 Dec 2021

Telomeric DNA damage response may increase susceptibility of elderly people to COVID-19

SARS-CoV-2 causes the pandemic coronavirus disease COVID-19, that is more harmful for elderly people, who show more severe symptoms and are at higher risk of hospitalization and death.

3 Dec 2021

Study reveals a previously unknown mechanism for pancreatic cancer metastasis

Pancreatic cancer is very aggressive and, unfortunately, has a poor prognosis with a 5-year survival of only 5%. Most deaths related to pancreatic cancer are due to metastasis, which occurs when the tumour invades other organs.

29 Nov 2021

Study involving a rat model offers potential treatment for Alexander disease

Alexander disease is a progressive and rare neurological disorder with no cure or standard course of treatment. But a new study led by researchers at the University of Wisconsin–Madison involving a rat model of the disease offers a potential treatment for the typically fatal condition.

18 Nov 2021

Rapid thermal cycling approach for the detection of SARS-CoV-2

Researchers develop an ultrafast detection method for SARS-CoV-2 by direct RT-PCR without RNA extraction that is suitable for large-scale use.

15 Nov 2021

Aptamer Group and DeepVerge expand partnership for Optimer-enabled wastewater monitoring

Aptamer Group Ltd., the developer of Optimer® binders to enable innovation in the life science industry, is pleased to announce the expansion of its existing partnership with DeepVerge PLC.

4 Nov 2021

$9 million grant from ASAP initiative to help advance research on Parkinson’s disease treatments

Researchers around the world have tried many ways, and for many years, to generate neurons in the lab so they could study them better. Neurons-on-demand might also provide a therapeutic option for replacing neurons lost in neurodegenerative conditions, such as Parkinson's disease.

27 Oct 2021

Inhibition of SARS-CoV-2 helicase by single DNA lesions

In a paper, the impact of specific DNA lesions is investigated regarding the unwinding activity of NSP13.

18 Oct 2021

Nucleoside modifications suppress the potential of RNA to activate dendritic cells

A new paper shows that human TLR3, TLR7, and TLR8 receptors are activated with naturally occurring RNA, but this is eliminated once modified nucleosides such as m5C, m6A, m5U s2U, or pseudouridine are incorporated.

12 Oct 2021

Plasmonic sensing of isothermally amplified nucleic acids and single-molecule detection of SARS-CoV-2

A new study finds that plasmonic sensing of LAMP amplicons through DNA hybridization enables highly specific detection of SARS-CoV-2 RNA.

11 Oct 2021

Design of mRNA vaccines to combat COVID-19

A recent review study discusses fundamental concepts in the successful delivery of nucleic acids in therapeutics.

23 Sep 2021

The role of nanomaterials during the COVID-19 pandemic

A new review published in Rare Metals has focused on the applications of nanomaterials to fight the ongoing COVID-19 pandemic.

22 Sep 2021

Aptamers for Targeting SARS-CoV-2 Proteins

AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of aptamers targeting SARS-CoV-2 proteins to aid development of new kits and assays.

From AMS Biotechnology 15 Sep 2021

Researchers find a way to turn SARS-CoV-2’s virulence mechanism against itself

A recent study, currently available on the bioRxiv* preprint server, reveals that a specific region of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be targeted by antisense oligonucleotides to potently inhibit viral replication, and consequently the development of coronavirus disease (COVID-19).

12 Sep 2021

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

30 Aug 2021

Innovative therapeutic platform for blood-to-brain delivery of antisense oligonucleotide therapy

Antisense oligonucleotide (ASO) therapy has the potential to ameliorate many neurodegenerative diseases at the genetic level to suppress the production of harmful proteins or non-coding RNAs.

12 Aug 2021

Potential new treatment for mast cell cancers reduces tumor size and prevents organ infiltration

A potential new treatment for mast cell cancers reduces the number of mast cells by "mutating" the messenger RNA (mRNA) before it can deliver instructions for manufacturing the gene responsible for cell proliferation.

10 Aug 2021